
    
      A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Anti-tumour Activity of Ascending Doses of SHR9549 in Women with Estrogen
      Receptor (ER) Positive Human Epidermal Receptor (HER-2) Negative Advanced Breast Cancer
    
  